Mumbai: BMC on Monday announced that it has conducted a pilot study to check the efficacy of expensive treatment called antibodies cocktails – popularized by former US President Donald Trump – between 212 Covid-19 patients with minor to moderate infection.
RS 60,000 maintenance costs per patient, but BMC gets two antibody drugs, casingivab and IMdevimab, through donations.
This study, was conducted at the Seven Hills Hospital BMC-Run, Andheri, including 74 patients with at least one co-morbidity and the score CT scanned around eight of 25.
Dean Hospital Dr.
B Adsul said fever in all patients who fell in all patient 48 hours.
“Covid developed only in one patient (0.5%) whose oxygen increased, but the mortality rate fell 70%,” said Dr.
Adsul.
Senior BMC officials said living in hospitals were reduced to five to six days because they opposed the average time of 13 to 14 days needed for patients received here during the first and second wave.
Dr.
Adsul said 5% of patients had to undergo ICU treatment.
“The most important thing, there are no side effects reported in any patient,” he added.
The BMC press statement claims cocktails can be “financially beneficial” because patients can avoid hospitalization and “other expensive drugs”.
Saying that pressure on health staff will be reduced because treatment can be given in OPD, release adds that BMC will consider using monoclonal antibodies during the expected third wave.
A similar study was conducted among patients treated in private ICU in Seven Hills and NSCI Dome managed by H N N Reliance Hospital.
Dr.
CEO Dr.
Gianchandani said 70 patients were given free drugs.
“The level of hospitalization and death drastically in these patients, proves that it can be determined as a treatment line,” he added.